Announcement
01 Apr 2025
In April 2025, the US Department of Commerce launched a Section 232 investigation into the national security implications of importing pharmaceuticals, pharmaceutical ingredients, and related derivative products. In April 2026, the U.S. Administration concluded the investigation and imposed Section 232 tariffs on patented pharmaceutical imports.
Source
Sign in to access
Number of interventions
10
9 certainly harmful
1 likely harmful
0 liberalising
List of interventions
Implementation date
21 Jan 2029
Revocation date:
No revocation date
Announced: 01 Apr 2025
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As part of this proclamat...
Sign in to see more
Implementation date
29 Sep 2026
Revocation date:
No revocation date
Announced: 01 Apr 2025
FDI: Financial incentive
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. The proclamation offers pref...
Sign in to see more
Announced: 01 Apr 2025
Local operations incentive
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As a condition for receiving...
Sign in to see more
Announced: 01 Apr 2025
Tax or social insurance relief
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As part of this proclamation...
Sign in to see more
Announced: 01 Apr 2025
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. The measure sets a preferent...
Sign in to see more
Implemented: 02 Apr 2026
Import tariff
On 1 April 2025, the US Department of Commerce initiated a Section 232 investigation to assess the national security impacts of importing pharmaceuticals, pharmaceutical ingredients, and related deriv...
Sign in to see more
Implementation date
29 Sep 2026
Revocation date:
02 Apr 2030
Announced: 01 Apr 2025
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. The measure sets an ad valor...
Sign in to see more
Implementation date
29 Sep 2026
Revocation date:
30 Jul 2026
Announced: 01 Apr 2025
Import tariff
On 31 July 2026, the Department of Commerce issued a notice lifting the Section 232 tariff rate on patented pharmaceuticals and associated pharmaceutical ingredients that are products of the United...
Sign in to see more
Implementation date
31 Jul 2026
Revocation date:
No revocation date
Clarification: 30 Jul 2026
Import tariff In force
Recent update from 30 Jul 2026:
On 30 July 2026, U.S. Customs and Border Protection issued guidance on the implementation of the proclamation (CSMS #69395344). According to the guidance, heading 9903.04.65 applies to the companie...
Sign in to see more
Implementation date
No implementation date
Revocation date:
No revocation date
Announced: 01 Apr 2025
Import tariff
On 2 April 2026, the U.S. Administration issued a proclamation imposing Section 232 tariffs on imported patented pharmaceuticals and associated pharmaceutical ingredients. As part of this proclamation...
Sign in to see more
Related State Acts
Announced: 31 Jul 2026
United States of America: U.S. Administration lifts Section 232 tariff on patented pharmaceutical imports from the United Kingdom
Announced: 23 Apr 2026
United States of America: Agreement with Regeneron on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with AbbVie on Most-Favoured-Nation drug pricing and tariff exemption
Clarification: 02 Apr 2026
United States of America: Agreement with Johnson & Johnson on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Amgen on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Boehringer Ingelheim on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Bristol Myers Squibb on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Genentech on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Gilead on Most-Favoured-Nation drug pricing and tariff exemption
Clarification: 02 Apr 2026
United States of America: Agreement with GSK on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Merck on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Novartis on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Sanofi on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 01 Dec 2025
United States of America: U.S. Administration’s commitments under an agreement on pharmaceutical pricing with the United Kingdom
Announced: 01 Dec 2025
United Kingdom: UK Government’s commitments under an agreement on pharmaceuticals with the United States
Implemented: 02 Apr 2026
United States of America: Agreement with Eli Lilly on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Novo Nordisk on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with EMD Serono on Most-Favored-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: U.S. Administration announces deal with AstraZeneca for Most-Favoured-Nation drug pricing and temporary tariff exemptions
Clarification: 02 Apr 2026
United States of America: Agreement with Pfizer on most-favored-nation drug pricing and tariff exemption
Announced: 28 Jul 2025
United States of America: US Administration’s commitments under the "U.S.–EU Cooperation Agreement on Reciprocal, Fair and Balanced Trade"
Clarification: 31 Jul 2025
United States of America: U.S. Administration issues Executive Order to implement Most-Favoured-Nation prescription drug pricing
Clarification: 06 May 2026
United States of America: U.S. Administration imposes Section 232 tariffs on truck imports
Clarification: 14 Jan 2026
United States of America: U.S. Administration concludes Section 232 investigation on imports of processed critical minerals and derivative products
Original implementation: 01 Jan 2026
United States of America: U.S. Administration announces additional duties on the imports of timber, lumber and their derivative products to address national security concerns
Announced: 25 Feb 2025
United States of America: U.S. Administration announces 50% tariffs on copper products and its derivatives to address national security concerns
Threads
See all
United States: Section 232 Investigations
This GTA Thread tracks all Section 232 investigations initiated by the United States since 2018 under the Trade Expansion Act of 1962. These investigations assess whether imports of certain goods threaten U.S. national security by examining domestic capacity, supply chain vulnerabilities, and import dependence. Only investigations formally announced by the U.S. Government are included.
Published: 14 Aug 2025
123
interventions
1
jurisdictions
United States: Drug Pricing Agreements
This Thread tracks the U.S. Administration’s agreements with pharmaceutical companies. It is based on the Executive Order titled “Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.” These agreements include tariff relief measures for pharmaceutical companies in return for their commitments to implement most-favored-nation pricing for their drugs and to invest i...
Published: 11 Nov 2025
69
interventions
2
jurisdictions
Investigation-Triggered Trade Instruments
This Thread tracks investigation-triggered trade instruments. These policies resemble traditional trade remedies but they operate outside WTO disciplines (i.e. no multilateral framework defines what counts as injury, what evidence is required, or how remedies are calibrated). Examples include US Sections 301 and 232, China's Trade Barriers Investigation regulation, and the EU's Trade Barriers...
Published: 01 May 2026
129
interventions
30
jurisdictions
Harmful Trade Policy Measures
This Thread tracks harmful trade policy interventions affecting all products. Covering all types of interventions monitored by Global Trade Alert, it highlights how the yearly number of these measures has evolved over time.
Published: 04 Sep 2024
71862
interventions
194
jurisdictions
Harmful Trade Policy Interventions: Medical Goods
This Thread tracks harmful trade policy interventions affecting HS codes for medical consumables, equipment, medicines, vaccines, as well as chemicals used in pharmaceutical production. It covers all types of interventions monitored by Global Trade Alert since 2009. To identify relevant policy actions, the Global Trade Alert team focused on the identification of relevant HS codes following the pr...
Published: 09 Jan 2025
7516
interventions
152
jurisdictions
G7: Harmful Trade Policy Interventions
This Thread tracks harmful trade policy interventions introduced by G7 members since 2009. It covers all types of interventions monitored by Global Trade Alert.
Published: 13 Jan 2025
25927
interventions
38
jurisdictions
G20: Harmful Trade Policy Interventions
This Thread tracks harmful trade policy interventions introduced by G20 members since 2009. It covers all types of interventions monitored by Global Trade Alert.
Published: 15 Jan 2025
54799
interventions
121
jurisdictions